914 related articles for article (PubMed ID: 15452193)
1. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
2. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
[TBL] [Abstract][Full Text] [Related]
3. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
5. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).
Lanz TA; Hosley JD; Adams WJ; Merchant KM
J Pharmacol Exp Ther; 2004 Apr; 309(1):49-55. PubMed ID: 14718585
[TBL] [Abstract][Full Text] [Related]
6. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
7. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
9. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.
Lewis HD; Pérez Revuelta BI; Nadin A; Neduvelil JG; Harrison T; Pollack SJ; Shearman MS
Biochemistry; 2003 Jun; 42(24):7580-6. PubMed ID: 12809514
[TBL] [Abstract][Full Text] [Related]
10. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
11. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
[TBL] [Abstract][Full Text] [Related]
12. Beta-amyloid secretases and beta-amloid degrading enzyme expression in lens.
Li G; Percontino L; Sun Q; Qazi AS; Frederikse PH
Mol Vis; 2003 May; 9():179-83. PubMed ID: 12740567
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice.
Goldstein ME; Cao Y; Fiedler T; Toyn J; Iben L; Barten DM; Pierdomenico M; Corsa J; Prasad CV; Olson RE; Li YW; Zaczek R; Albright CF
J Pharmacol Exp Ther; 2007 Oct; 323(1):102-8. PubMed ID: 17640949
[TBL] [Abstract][Full Text] [Related]
14. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
Hyde LA; McHugh NA; Chen J; Zhang Q; Manfra D; Nomeir AA; Josien H; Bara T; Clader JW; Zhang L; Parker EM; Higgins GA
J Pharmacol Exp Ther; 2006 Dec; 319(3):1133-43. PubMed ID: 16946102
[TBL] [Abstract][Full Text] [Related]
15. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
[TBL] [Abstract][Full Text] [Related]
16. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
Nishitomi K; Sakaguchi G; Horikoshi Y; Gray AJ; Maeda M; Hirata-Fukae C; Becker AG; Hosono M; Sakaguchi I; Minami SS; Nakajima Y; Li HF; Takeyama C; Kihara T; Ota A; Wong PC; Aisen PS; Kato A; Kinoshita N; Matsuoka Y
J Neurochem; 2006 Dec; 99(6):1555-63. PubMed ID: 17083447
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein.
Irizarry MC; Deng A; Lleo A; Berezovska O; Von Arnim CA; Martin-Rehrmann M; Manelli A; LaDu MJ; Hyman BT; Rebeck GW
J Neurochem; 2004 Sep; 90(5):1132-43. PubMed ID: 15312168
[TBL] [Abstract][Full Text] [Related]
18. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
20. beta-Secretase, APP and Abeta in Alzheimer's disease.
Vassar R
Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
